CTT PHARMACEUTICAL HOLDINGS, INC.: 10-Q filed 2011-11-14
What CTT PHARMACEUTICAL HOLDINGS, INC. reported in its quarterly report filed 2011-11-14 (fiscal Q3 2011): 23 published measures, 72 facts as tagged in accession 0001204459-11-003019.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2011-11-14
- Fiscal period
- fiscal Q3 2011
- Accession
- 0001204459-11-003019 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CTT PHARMACEUTICAL HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,397,234 | USD | |
| At 2010-12-31 | 1,262,276 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 338,105 | USD | |
| At 2010-12-31 | 1,260,930 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,059,129 | USD | |
| At 2010-12-31 | -317,889 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -442,122 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 4,168,372 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -442,267 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -583,366 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -160,730 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -516,554 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -1,029,315 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -1,434,610 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 0 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -150,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -94,977 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 1,402,316 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 0 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 1,321,980 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 0 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 0 | USD | 273 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 8,903,015 | shares | 92 |
| 2011-01-01 to 2011-09-30 | 8,891,125 | shares | 273 |
| 2010-07-01 to 2010-09-30 | 8,533,419 | shares | 92 |
| 2010-01-01 to 2010-09-30 | 8,333,907 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 8,903,015 | shares | 92 |
| 2011-01-01 to 2011-09-30 | 9,402,663 | shares | 273 |
| 2010-07-01 to 2010-09-30 | 8,533,419 | shares | 92 |
| 2010-01-01 to 2010-09-30 | 8,333,907 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -0.05 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | 0.47 | USD/shares | 273 |
| 2010-07-01 to 2010-09-30 | -0.05 | USD/shares | 92 |
| 2010-01-01 to 2010-09-30 | -0.07 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -0.05 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | 0.44 | USD/shares | 273 |
| 2010-07-01 to 2010-09-30 | -0.05 | USD/shares | 92 |
| 2010-01-01 to 2010-09-30 | -0.07 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 0 | USD | |
| At 2010-12-31 | 426,396 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 0 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 155,396 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 133,228 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 154,408 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -107,420 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -571,048 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -981,647 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -1,510,281 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 739,533 | USD | |
| At 2010-12-31 | 519,662 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 338,105 | USD | |
| At 2010-12-31 | 944,712 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 107,420 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 571,048 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 981,647 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 1,510,281 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 8,960,081 | shares | |
| At 2010-12-31 | 8,885,081 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 12,383,641 | USD | |
| At 2010-12-31 | 12,228,245 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | -105,985 | USD | |
| At 2010-12-31 | -105,985 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,059,129 | USD | |
| At 2010-12-31 | 1,346 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -107,915 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -565,868 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -867,191 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -1,038,649 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 41,733 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 264,966 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 223,397 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 304,450 | USD | 273 |
Inspect the source
- Entity
- CTT PHARMACEUTICAL HOLDINGS, INC. / CIK 0001035422
- Captured
- 2026-09-20T05:15:10.936Z
- SEC response SHA-256
21b0a0ba4c84772224f4978cbe9507956b8d731d5fe56b447e41295eab5239b0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035422.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))